{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:43Z","timestamp":1792268623340,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109305","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:28:33Z","timestamp":1770222513000},"page":"109305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis"],"prefix":"10.1016","volume":"214","author":[{"given":"Hidetoshi","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-3350","authenticated-orcid":false,"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5232","authenticated-orcid":false,"given":"Pongwut","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-4533","authenticated-orcid":false,"given":"Adlinda","family":"Alip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-6477","authenticated-orcid":false,"given":"Soon-Hin","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-417X","authenticated-orcid":false,"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Nahit \u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9294-2146","authenticated-orcid":false,"given":"Alianu","family":"Akawung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fennema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109305_b0005","unstructured":"World Health Organization, Global Cancer Observatory: Cancer Today; Asia. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/935-asia-fact-sheet.pdf, 2024 (accessed December 22, 2025)."},{"key":"10.1016\/j.lungcan.2026.109305_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241231260","article-title":"Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology","volume":"16","author":"Laguna","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0015","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jtho.2023.06.014","article-title":"Lung cancer screening in Asia: an expert consensus report","volume":"18","author":"Lam","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1513\/pats.201107-042ST","article-title":"American Thoracic Society, International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: executive summary","volume":"8","author":"Travis","year":"2011","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.lungcan.2026.109305_b0025","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lungcan.2026.109305_b0030","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109305_b0035","doi-asserted-by":"crossref","unstructured":"G.J. Riely, D.E. Wood, D.S. Ettinger, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, M. DeCamp, A.P. Desai, T.J. Dilling, J. Dowell, G.A. Durm, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Juloori, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T.C. Mullikin, T. Ng, D. Owen, D.H. Owen, S.P. Patel, T. Patil, P.M. Polanco, J. Riess, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K.M. Gregory, L. Hang, Non\u2013Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw. 22 (2024) 249\u2013274, https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","DOI":"10.6004\/jnccn.2204.0023"},{"key":"10.1016\/j.lungcan.2026.109305_b0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"ESMO guidelines committee, oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0045","unstructured":"RYBREVANT\u00ae (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; Revised September 2024."},{"key":"10.1016\/j.lungcan.2026.109305_b0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA investigators, Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Flaura investigators, overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0060","first-page":"1","article-title":"First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo Lama","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0065","article-title":"Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis","volume":"3","author":"Chan","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109305_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143362","article-title":"Overall survival benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review and network meta-analysis","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109305_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100115","article-title":"A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903","volume":"6","author":"Ito","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109305_b0080","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/j.jtho.2023.09.1247","article-title":"EP12.01-31 Updated first-line osimertinib in Asian patients with advanced EGFR-mutated lung cancer","volume":"18","author":"Tan","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0085","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231216089","article-title":"Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib","volume":"15","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0090","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109305_b0095","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0100","doi-asserted-by":"crossref","unstructured":"S.S. Ramalingam, Y. Cheng, C. Zhou, Y. Ohe, F. Imamura, B.C. Cho, M.-C. Lin, M. Majem, R. Shah, Y. Rukazenkov, A. Todd, A. Markovets, J.C. Barrett, J. Chmielecki, J. Gray, Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study, Ann. Oncol. 29 (2018) VIII740. Abstract LBA750, https:\/\/doi.org\/10.1093\/annonc\/mdy424.063.","DOI":"10.1093\/annonc\/mdy424.063"},{"key":"10.1016\/j.lungcan.2026.109305_b0105","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109305_b0110","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1556-0864(23)00273-3","article-title":"Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: a real-world, US attrition analysis","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40801-022-00302-w","article-title":"Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data","volume":"9","author":"Nieva","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.lungcan.2026.109305_b0120","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/j.jtho.2022.07.764","article-title":"EP08.02-082 treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study","volume":"17","author":"Lee","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0125","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 investigators, Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0130","doi-asserted-by":"crossref","unstructured":"D. Planchard, P.A. J\u00e4nne, K. Kobayashi, J.C.H. Yang, Y. Liu, N. Valdiviezo, T.M. Kim, L. Jiang, H. Kagamu, N. Yanagitani, J. Wang, B. Biswas, A. Poltoratskiy, Y. Neron, C. Rojas, L. Koubkova, C. Escriu, D. Ezeife, K. Barrett, M. Albayaty, H. Jiang, C.K. Lee, First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival, Presented at: IASLC 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain.","DOI":"10.1016\/j.jtho.2025.09.015"},{"key":"10.1016\/j.lungcan.2026.109305_b0135","doi-asserted-by":"crossref","unstructured":"J.C.-H. Yang, K. Kobayashi, B. Chewaskulyong, T.V. Tran, B. Biswas, K.H. Lee, P.H. Feng, X.D. Pham, Y. Yao, S. Kuyama, J.Y. Tan Chun Bing, R. Bhise, M.-J. Ahn, V. Sriuranpong, R.K. Li, E. Armenteros Monterroso, K. Barrett, M. Albayaty, Y. Cheng, 630MO First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort, Ann. Oncol. 35 (2024) S1635\u2013S1636, https:\/\/doi.org\/10.1016\/j.annonc.2024.10.663.","DOI":"10.1016\/j.annonc.2024.10.663"},{"key":"10.1016\/j.lungcan.2026.109305_b0140","doi-asserted-by":"crossref","unstructured":"P.A. Janne, D. Planchard, K. Kobayashi, J.C. Yang, Y. Liu, N. Valdiviezo, T.M. Kim, L. Jiang, H. Kagamu, N. Yanagitani, J. Wang, B. Biswas, A. Poltoratskiy, Y. Neron, C. Rojas, L. Koubkova, C. Escriu, D.A. Ezeife, H. Mann, E. Armenteros-Monterroso, Y. Rukazenkov, C.K. Lee, FLAURA2 Investigators, Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC, N. Engl. J. Med. 394 (2026) 27\u201338, https:\/\/doi.org\/10.1056\/NEJMoa2510308.","DOI":"10.1056\/NEJMoa2510308"},{"key":"10.1016\/j.lungcan.2026.109305_b0145","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor\u2013resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109305_b0150","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109305_b0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109305_b0160","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors","volume":"17","author":"Cho","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0165","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC): results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0170","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"MARIPOSA investigators, amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0175","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0180","unstructured":"H. Hayashi, B. Besse, S.H. Lee, S. Lu, D. Nguyen, S. Popat, J.C.H. Yang, M. Gottfried, J.M. Dias, C. Martin, M.A.N. \u015eendur, L. Paz-Ares, S. Owen, M.D.R.G. Campelo, B. Wang, S. Sethi, S. Shah, J. Zhang, J.C. Curtin, B.C. Cho, Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA, Presented at: World Conference on Lung Cancer (WCLC); September 6-9, 2025; Barcelona, Spain."},{"key":"10.1016\/j.lungcan.2026.109305_b0185","unstructured":"Johnson & Johnson, European Commission approves RYBREVANT\u00ae (amivantamab) in combination with LAZCLUZE\u00ae (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer, (2024)."},{"key":"10.1016\/j.lungcan.2026.109305_b0190","unstructured":"RYBREVANT\u00ae (amivantamab-vmjw) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; Revised 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0195","unstructured":"RYBREVANT\u00ae (amivantamab) concentrate for solution for infusion, [package insert]. Macquarie Park, Australia: Janssen-Cilag Pty Ltd, 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0200","unstructured":"RYBREVANT\u00ae concentrate for solution for infusion 50 mg\/ml [package insert]. Research Triangle Park, North Carolina, USA: Biogen Inc., 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0205","unstructured":"RYBREVANT\u00ae injection (Amivantamab) [product information], 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0210","unstructured":"RYBREVANT\u00ae Intravenous Infusion 350 mg [package insert]. Chiyoda-ku, Tokyo: Janssen Pharmaceutical K.K., 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0215","unstructured":"RYBREVANT\u00ae (amivantamab) concentrate for solution for infusion [package insert]. Singapore: Johnson & Johnson International (Singapore) Pte. Ltd."},{"key":"10.1016\/j.lungcan.2026.109305_b0220","unstructured":"RYBREVANT\u00ae (amivantamab) injection [package insert]. Schaffhausen, Switzerland: Cilag AG, 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108496","article-title":"Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset","volume":"204","author":"Cho","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109305_b0230","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd.2017.07.57","article-title":"Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer","volume":"9","author":"Li","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2026.109305_b0235","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3904\/kjim.2015.158","article-title":"Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer","volume":"33","author":"Baek","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.lungcan.2026.109305_b0245","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JGO.2016.003392","article-title":"Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer","volume":"3","author":"Bhatt","year":"2017","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0250","doi-asserted-by":"crossref","first-page":"A276","DOI":"10.1016\/j.chest.2016.02.288","article-title":"Impact of ethnicity on the initial incidence of brain metastasis in patients with EGFR-mutant lung cancer","volume":"149","author":"Zhang","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2026.109305_b0255","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0260","doi-asserted-by":"crossref","unstructured":"A.I. Spira, M.B. Sauder, J. Feldman, J. Smith, N. Girard, W. Li, F. Bozorgmehr, M. Mak, T. Romero, Y. Xia, S. Sheng, M. Nematian-Samani, J. Simoes, M. Wildgust, B.C. Cho, First results from the COCOON Treatment Substudy in managing moderate to severe dermatologic adverse events in participants with EGFR-mutated advanced NSCLC treated with first-line amivantamab-lazertinib, Poster presented at the IASLC | ASCO North America Conference on Lung Cancer (NACLC); December 5\u20137, 2025; Chicago, IL, USA.","DOI":"10.1016\/j.jtho.2026.103870"},{"key":"10.1016\/j.lungcan.2026.109305_b0265","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cllc.2024.04.004","article-title":"Risk of venous thromboembolism in patients with stage III and IV non-small-cell lung cancer: nationwide descriptive cohort study","volume":"25","author":"Ording","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109305_b0270","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous amivantamab\u2014results from SKIPPirr, a phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109305_b0275","doi-asserted-by":"crossref","unstructured":"N.B. Leighl, H. Akamatsu, S.M. Lim, Y. Cheng, A.R. Minchom, M.E. Marmarelis, R.E. Sanborn, J. Chih-Hsin Yang, B. Liu, T. John, B. Massuti, A.I. Spira, S.H. Lee, J. Wang, J. Li, C. Liu, S. Novello, M. Kondo, M. Tamiya, E. Korbenfeld, M. Moskovitz, J.Y. Han, M. Alexander, R. Joshi, E. Felip, P.J. Voon, P. Danchaivijitr, P.C. Hsu, F.J. Silva Melo Cruz, T. Wehler, L. Greillier, E. Teixeira, D. Nguyen, J.K. Sabari, A. Qin, D. Kowalski, M.A. Nahit Sendur, J. Xie, D. Ghosh, A. Alhadab, N. Haddish-Berhane, P.L. Clemens, P. Lorenzini, R.B. Verheijen, M. Gamil, J.M. Bauml, M. Baig, A. Passaro, PALOMA-3 Investigators, Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer: primary results from the phase III PALOMA-3 study, J. Clin. Oncol. 42 (2024) 3593\u20133605, https:\/\/doi.org\/10.1200\/JCO.24.01001.","DOI":"10.1200\/JCO.24.01001"},{"key":"10.1016\/j.lungcan.2026.109305_b0280","unstructured":"Johnson & Johnson, European Commission approves subcutaneous RYBREVANT\u00ae\u25be (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer, (2025)."},{"key":"10.1016\/j.lungcan.2026.109305_b0285","unstructured":"RYBREVANT FASPRO\u2122 (amivantamab and hyaluronidase-lpuj) injection, for subcutaneous use [package insert]. Horsham, PA, USA: Janssen Biotech, Inc. 2025."},{"key":"10.1016\/j.lungcan.2026.109305_b0290","unstructured":"RYBREVANT FASPRO\u2122 is for subcutaneous use only [package insert]. Cilag AG, Schaffhausen, Switzerland."},{"key":"10.1016\/j.lungcan.2026.109305_b0295","unstructured":"RYBROFAZ\u00ae combination subcutaneous injection [package insert]. Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:48:18Z","timestamp":1790700498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":59,"alternative-id":["S0169500226000498"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109305","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109305"}}